A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE012 (BRA) · Dr. Kowalski
consented 2022-06-12
AEs
4
Serious
0
Dropout signal
–
Adverse events
mild
assessed
Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-07-07 (study day 8); relationship: not assessed
mild
assessed
Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-11-23 (study day 147); relationship: N
mild
assessed
Grade 1 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-01-13 (study day 198); relationship: not assessed
moderate
assessed
Grade 2 Vomiting — outcome: RECOVERED/RESOLVED; onset 2023-01-28 (study day 213); relationship: not assessed
Data queries
No data queries.